6dge: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='6dge' size='340' side='right'caption='[[6dge]], [[Resolution|resolution]] 1.91Å' scene=''> | <StructureSection load='6dge' size='340' side='right'caption='[[6dge]], [[Resolution|resolution]] 1.91Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6dge]] is a 1 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6dge]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6DGE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6DGE FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.91Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GBG:N~6~-[(1E)-2-chloroethanimidoyl]-L-lysine'>GBG</scene></td></tr> | |||
<tr id=' | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6dge FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6dge OCA], [https://pdbe.org/6dge PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6dge RCSB], [https://www.ebi.ac.uk/pdbsum/6dge PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6dge ProSAT]</span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/DDAH1_HUMAN DDAH1_HUMAN] Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 21: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 6dge" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6dge" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Burstein-Teitelbaum | [[Category: Burstein-Teitelbaum G]] | ||
[[Category: Er | [[Category: Er JAV]] | ||
[[Category: Fast | [[Category: Fast W]] | ||
[[Category: Monzingo | [[Category: Monzingo AF]] | ||
[[Category: Tuley | [[Category: Tuley A]] | ||
Latest revision as of 09:05, 11 October 2023
Crystal structure of the dimethylarginine dimethylaminohydrolase adduct with N5-(1-imino-2-chloroethyl)-L-lysineCrystal structure of the dimethylarginine dimethylaminohydrolase adduct with N5-(1-imino-2-chloroethyl)-L-lysine
Structural highlights
FunctionDDAH1_HUMAN Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. Publication Abstract from PubMedInhibitors of the human enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH1) can control endogenous nitric oxide production. A time-dependent covalent inactivator of DDAH1, N(5)-(1-imino-2-chloroethyl)-l-ornithine ( KI = 1.3 muM, kinact = 0.34 min(-1)), was conceptually dissected into two fragments and each characterized separately: l-norvaline ( Ki = 470 muM) and 2-chloroacetamidine ( KI = 310 muM, kinact = 4.0 min(-1)). This analysis suggested that the two fragments were not linked in a manner that allows either to reach full affinity or reactivity, prompting the synthesis and characterization of three analogues: two that mimic the dimethylation status of the substrate, N(5)-(1-imino-2-chloroisopropyl)-l-ornithine ( kinact /KI = 208 M(-1) s(-1)) and N(5)-(1-imino-2-chlorisopropyl)-l-lysine ( kinact /KI = 440 M(-1) s(-1)), and one that lengthens the linker beyond that found in the substrate, N(5)-(1-imino-2-chloroethyl)-l-lysine (Cl-NIL, KI = 0.19 muM, kinact = 0.22 min(-1)). Cl-NIL is one of the most potent inhibitors reported for DDAH1, inactivates with a second order rate constant (1.9 x 10(4) M(-1) s(-1)) larger than the catalytic efficiency of DDAH1 for its endogenous substrate (1.6 x 10(2) M(-1) s(-1)), and has a partition ratio of 1 with a >100000-fold selectivity for DDAH1 over arginase. An activity-based protein-profiling probe is used to show inhibition of DDAH1 within cultured HEK293T cells (IC50 = 10 muM) with cytotoxicity appearing only at higher concentrations (ED50 = 118 muM). A 1.91 A resolution X-ray crystal structure reveals specific interactions made with DDAH1 upon covalent inactivation by Cl-NIL. Dissecting a covalent inactivator and analysis of its constituent fragments proved useful for the design and optimization of this potent and effective DDAH1 inhibitor. Dissection, Optimization, and Structural Analysis of a Covalent Irreversible DDAH1 Inhibitor.,Burstein-Teitelbaum G, Er JAV, Monzingo AF, Tuley A, Fast W Biochemistry. 2018 Jul 20. doi: 10.1021/acs.biochem.8b00554. PMID:29983043[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
|